Introduction
The sphingomyelin pathway is initiated by the rapid hydrolysis of plasma membrane sphingomyelin to the second messenger ceramide via the action of a sphingomyelinase (Kolesnick and Paley, 1987; Okazaki et al., 1989) . Mammalian cells utilize three distinct forms of sphingomyelinases, that are discriminated by their pH optimum, the acid, neutral and alkaline sphingomyelinases, to effect ceramide generation. Only the acid sphingomyelinase (ASM) and the neutral sphingomyelinase are known to be involved in signal transduction in mammalian cells. While ASM was cloned in the early 1990s by Schuchman and co-workers (Schuchman et al., 1991) , and there are many excellent reagents for studying its biological significance, NSMs have only recently been defined at the molecular level. A potential signaling function of the alkaline sphingomyelinase has still to be elucidated. Alternatively, ceramide can be synthesized de novo via a pathway regulated by the enzymes serine-palmitoyl-transferase and ceramide synthase. Evidence suggests that ceramide generated by this mechanism may also be involved in some instances in stress signaling.
Over the past decade, steady progress has been made in defining the clinical relevance of sphingomyelin/ ceramide signaling in various clinically related settings. Ceramide may be a key mediator of some radiation-and chemotherapeutic responses of tumors (Santana et al., 1996; Morita et al., 2000; Pena et al., 2000; Paris et al., 2001; Garcia-Barros et al., 2003) , the infectious program of some bacteria and viruses (Grassme´et al., 1997 Jan et al., 2000; Esen et al., 2001) , the pathogenesis of hereditary sensory neuropathy type I (Bejaoui et al., 2001; Dawkins et al., 2001) , heat damage, UVA light and ischemia-reperfusion injury (Yu et al., 2000; Zhang et al., 2001; Chung et al., 2003) -to list a few examples. In some settings, ceramide is also required for induction of apoptosis by CD95 (Cifone et al., 1994; Gulbins et al., 1995; Cremesti et al., 2001; ) and the TNF receptor (Schu¨tze et al., 1992) , and during the physiological process of oocyte atresia (Morita et al., 2000) .
Here, we discuss our developing understanding of the role of ceramide in the pathogenesis and treatment of disease. We provide a mechanistic model for the ceramide-dependent reorganization of membranes into signaling compartments that may relate to disease progression and treatment. We confine the review to the role of ASM-generated ceramide in these processes, as recent concepts are based on biochemical, biological and translational insights derived primarily from the topographical actions of ASM within membranes.
Biomedical functions of ASM and ceramide

ASM-released ceramide mediates apoptosis upon radiation, UVA light and ischemia-reperfusion injury
Several studies indicate a role for ASM and ceramide in the cellular response to ionizing radiation (Santana et al., 1996; Morita et al., 2000; Pena et al., 2000; Paris et al., 2001; Garcia-Barros et al., 2003) . Diverse cells activate ASM and release ceramide within seconds to minutes after irradiation. Activation of ASM occurred in the plasma membrane of irradiated cells and correlated closely with apoptosis induction. Genetic deficiency of ASM in cells derived from patients with Niemann-Pick disease type A prevented radiation-induced ceramide release and apoptosis, and reintroduction of ASM restored these radiation effects (Santana et al., 1996) , indicating that ASM mediates apoptosis via ceramide, at least in some cells. These in vitro findings were recapitulated in ASM-deficient mice (Santana et al., 1996) . Mature B cells, endothelial cells or mesothelium of these mice were resistant to radiation-induced cell death, providing genetic proof for the requirement of ASM for cell death upon radiation. Further, embryonic fibroblasts from these mice were resistant ex vivo to radiation, which was reversed by exogenous addition of nanomolar concentrations of natural C 16 -ceramide. However, some other cell types, for example, thymocytes, remained sensitive to radiation in ASM-deficient mice while manifesting resistance in a p53
À/À background. These studies indicate that radiation effects are mediated by different mechanisms depending on the cell type.
Further studies identified endothelial cells as primary targets for radiation-induced apoptosis regulated by ASM expression (Pena et al., 2000; Paris et al., 2001; Garcia-Barros et al., 2003) . Radiation of the central nervous system in C57Bl/6 or C3H/HN mice results in dose-dependent apoptosis in up to 20% of the cells within the first 12 h (Pena et al., 2000) . As much as 20% of all apoptotic cells were confirmed as endothelial cells. In contrast, ASM knockout mice were resistant to irradiation, as endothelial and other cells of the central nervous system remained TUNEL negative after doses as high as 40 Gy.
The central role of ASM-mediated apoptosis in endothelial cells for the radiation response was detailed in the following two models GarciaBarros et al., 2003) . Whole-body radiation of mice resulted in the death of C57Bl/6 mice within 12-14 days, caused by depletion of bone marrow elements, from which they could be rescued by marrow transplantation . However, an increase in dose to 15 Gy altered the mode of death, with animals dying within 6-8 days from the gastrointestinal (GI) syndrome. The GI syndrome results from radiation-induced depletion of villi and crypts, resulting in loss of the barrier and resorptive functions of the GI tract, which, if severe, can be lethal. An analysis of the molecular mechanisms mediating the GI syndrome detected apoptosis of endothelial cells as early as 1 h and peaking at 4 h after 8-15 Gy irradiation, preceding the onset of apoptosis of epithelial cells in the crypts and villi observed 8-10 h after irradiation. The extent of endothelial cell apoptosis correlated closely with the onset of the GI syndrome as massive endothelial apoptosis was detected at 15 Gy, the switchpoint between death from marrow depletion to GI death. Radiation-induced apoptosis of endothelial cells in the GI tract was prevented by ASM deficiency or intravenous injection of bFGF that blocked ASM-induced generation of ceramide. ASM deficiency or treatment with bFGF also protected animals from development of the GI syndrome even at doses as high as 17 Gy. Critically, endothelial but not crypt stem cells displayed FGF receptors, indicating that the protection afforded must be via the microvasculature. These data indicate that expression of ASM is required for apoptosis in endothelial cells in the GI tract upon radiation, an event necessary for GI tract dysfunction.
Recent studies on the response of tumors to radiotherapy confirmed the notion that ASM-mediated apoptosis of endothelial cells is central to some tissue responses to radiation (Garcia-Barros et al., 2003) (Figure 1 ). In these studies, B16F1 melanoma or MCA/129 fibrosarcoma were transplanted into normal and ASM-deficient mice. It is important to note that both types of mice were transplanted with the same tumors, and that any differences in growth and response of the tumors to radiation are thus caused by the differential expression of ASM in the host. The data showed that the tumors grew 2-4 times faster in the ASM-deficient background than in normal mice. Moreover, tumors grown in normal mice were radiosensitive, for instance, the MCA/129 fibrosarcomas respond to 15 Gy with a 70% decrease of tumor size, while the tumors grown in the ASM-deficient mice were resistant, continuing to grow at their original rate. Further analysis revealed that the differential tumor radiosensitivity reflected differential apoptosis in endothelial cells in the tumor microvasculature. Endothelial cells lacking ASM were resistant to radiation-induced cell . Transplantation of normal marrow cells into ASM knockout mice resulted in incorporation of ASM-replete precursors into the tumor vessels and restored the radiosensitivity of the tumor (Garcia-Barros et al., 2003) . Vice versa, transplantation of normal mice with marrow from ASM-deficient mice resulted in resistance of the tumor to radiation. These data show that the ASM is a primary target for radiation and is required for radiation-induced apoptosis, at least in some cell types. Radiation-induced microvascular dysfunction may cause local ischemia, a bystander effect or leakage of circulating elements that might impact tumor cell viability. Further, microvascular dysfunction may act in concert with DNA double-strand breaks within tumor cells to effect tumor regression. Additional studies appear necessary to distinguish which of these possibilities are operative in the tumor response to ionizing radiation. Separate studies identified oocytes as another cell type whose radiosensitivity is regulated by ASM (Morita et al., 2000; Paris et al., 2002) . Irradiation of ASMpositive mice yielded rapid oocyte apoptosis, while ASM deficiency protected oocytes against this apoptotic effect. Likewise, ASM deficiency protected oocytes from doxorubicin-triggered apoptosis. Oocytes were also rescued from radiation or chemotherapy-induced apoptosis by treatment with the ceramide metabolite sphingosine 1-phosphate, which serves as a functional antagonist of ceramide action. Cytostatic drugs that may, in some cells, employ ASM for the induction of apoptosis include doxorubicin (Morita et al., 2000) and paclitaxel (E Gulbins, unpublished data). As preservation of ovarian function by sphingosine 1-phosphate prevented radiation-induced sterility without evidence for propagated mutations in the progeny of irradiated mice, it may be possible to develop sphingosine 1-phosphate or an analog to preserve fertility in young girls or women undergoing cancer treatment. Studies directed at this issue are currently underway.
Similar to the function of the ASM in radiationinduced cell death, the enzyme appeared central for apoptosis induction by UVA light (Zhang et al., 2001) . Normal cells respond to UVA light with rapid activation of ASM, release of ceramide and activation of c-Jun N-terminal kinase (JNK) that finally appeared to trigger apoptosis. In contrast, UVA light did not trigger JNK activation or apoptosis in ASM-deficient B lymphocytes, suggesting an early and central role of ASMreleased ceramide in the apoptotic response to this environmental stress. Whether this finding is relevant to the clinical uses of UV light is currently unknown.
Ischemic stroke is an additional example of a potentially significant role for ASM in a medically relevant problem. Mattson et al. demonstrated that the infarcted area upon occlusion of the middle cerebral artery was much smaller in ASM-deficient mice than in normal mice (Yu et al., 2001 ). This correlated with less behavioral sequelae in ASM-deficient mice than their wild-type littermates. While the mechanism for the protection of ASM-deficient mice during ischemic stroke is unknown, it is tempting to speculate that ASM might be involved in determining the fate of microvessels following the initial stroke phase regulating the death of cells in the infarct penumbra. Alternatively, it remains possible that the deficiency of ASM protects neurons directly from stress-induced death.
ASM in autoimmune syndromes
Two distinct autoimmune models provided further evidence for a potentially important role for ASMmediated apoptosis in clinical medicine. Intravenous injection of phytohemagglutin (PHA) results in a CD95-dependent autoimmune hepatitis (Seino et al., 1997) . This syndrome is caused by induction of CD95 ligand on lymphocytes upon PHA stimulation and migration of these lymphocytes to the liver. Since hepatocytes constitutively express CD95, they are killed by apoptosis upon contact with the CD95 ligand-positive T cells, resulting in autoimmune hepatitis (Seino et al., 1997) . ASM-deficient mice were protected against the adverse effects of PHA injections despite normal upregulation of CD95 on their T cells, and the livers in ASM knockout mice were almost free of apoptotic cells (Kirschnek et al., 2000) . As PHA-induced hepatitis is regarded as a model for acute T-cell-mediated autoaggressive liver disorder, ASM may represent a previously unrecognized target for therapeutic intervention.
A second model employed the finding that ligation of CD4 on T cells results in apoptosis of these cells (Wang et al., 1994) . Ligation of CD4 is induced in vivo, for example, by binding of the HIV receptor molecule gp120, and can be mimicked by injection of anti-CD4 antibodies. Depletion of T cells upon CD4 ligation is mediated by activation of the endogenous CD95 and CD95 ligand system (Wang et al., 1994) . Studies on ASM-deficient mice revealed that CD4 T cells lacking ASM were resistant to apoptosis induction in vivo upon injection of anti-CD4 antibodies, while ASM-positive CD4 T cells died (Kirschnek et al., 2000) . These two models suggest that ASM may be central for CD95 ligand/CD95-induced apoptosis in vivo in some circumstances. Whether ceramide plays a role in the apoptosis of HIV-infected CD4-positive lymphocytes has to be determined.
ASM in development and physiological cell turnover
In addition to mediating apoptosis by exogenous stimuli, ASM has been implicated in developmental apoptosis, in at least some cell types. Tilly and coworkers (Morita et al., 2000) described that the normal deletion of oocytes in the ovary is greatly affected in ASM-deficient mice. Normal mice delete approximately 80% of all oocytes by apoptosis prior to birth, followed by a continued apoptosis throughout adult life. Genetic deficiency of ASM markedly attenuated developmental oocyte apoptosis, resulting in a twofold increase in oocytes at birth that was maintained throughout life. Recent results from J. Lord's group that ASM deficiency delayed spontaneous apoptosis of neutrophils that are programmed to die within 2-4 days after release from the bone marrow into the peripheral blood (personnel communication), confirming a role of ASM in normal cell/tissue turnover. Whether an increase of ceramide is related to disorders characterized by neutropenia of unknown etiology, for example, idiopathic neutropenia, white-cell aplasia, myelodysplasia or aplastic anemia, has to be determined.
ASM mediates bacterial and viral infections
Several recent studies indicated that the ASM has a central role in the infection of mammalian cells with microbial pathogens (Grassme´et al., 1997 Jan et al., 2000; Esen et al., 2001) . Initial studies showed that infection of epithelial phagocytic cells with pathogenic Neisseria gonorrhoeae activates ASM and results in the release of ceramide within infected cells (Grassme´et al., 1997; Hauck et al., 2000) . The significance of these findings was underscored by experiments demonstrating that ASM-deficient fibroblasts, or phagocytes treated with two inhibitors of ASM, were unable to internalize N. gonorrhoeae.
The notion that ASM plays an important role in at least some bacterial infections was recently confirmed by studies on the infection of epithelial cells with Pseudomonas aeruginosa (Grassme´et al., 1997). P. aeruginosa is a Gram-negative bacteria infecting predominantly immunocompromised patients, ventilated patients or patients with large open wounds. Most importantly, children with cystic fibrosis develop a chronic pulmonary infection with P. aeruginosa that eventually leads to pulmonary destruction and their early demise. P. aeruginosa activates ASM and triggers the release of ceramide within minutes of infection. ASM activity was required for the internalization of P. aeruginosa into lung epithelial cells, the induction of apoptosis in these infected lung epithelial cells and the regulation of the innate immune response release of proinflammatory cytokines into the lung during infection. ASM deficiency greatly sensitized the mice to P. aeruginosa pneumonia. These mice were unable to control the pulmonary P. aeruginosa infection and died from sepsis within days. Death was caused by a massive unregulated release of proinflammatory cytokines from the lung of these animals. This indicates a principal role of ASM in the pulmonary defense against P. aeruginosa infections.
Further studies on Staphylococcus aureus (Esen et al., 2001) and Sindbis virus (Jan et al., 2000) extend the list of already known pathogens that infect cells via ASM activation and generation of ceramide. Genetic deficiency of ASM or pharmacologic inhibition of the enzyme reduces or even prevents infection of mammalian cells with these pathogens. P. falciparum seems to have developed another strategy to circumvent a requirement for endogenous ASM, that is, the pathogen expresses its own sphingomyelinase that appears to be required for the infection of erythrocytes with P. falciparum (Hanada et al., 2002) . Targeting endogenous ASM or the pathogen's sphingomyelinase might serve as a novel strategy to alter the course of these infections.
ASM and death receptor-mediated apoptosis
Several studies showed that stimulation via CD95 (Cifone et al., 1994; Gulbins et al., 1995; Cremesti et al., 2001; or tumor necrosis factor receptor (Schu¨tze et al., 1992; Garcia-Ruiz et al., 2003) results in rapid ASM activation and release of ceramide. Human B lymphocytes or fibroblasts from Niemann-Pick disease type A patients, who suffer from an inborne deficiency of ASM, and ex vivo splenocytes or hepatocytes from ASM knockout mice were resistant to CD95 or TNF-R stimulation (Kirschnek et al., 2000; Paris et al., 2000; Garcia-Ruiz et al., 2003) . Expression of ASM or addition of natural C 16 -ceramide to ASM-deficient cells restored CD95-triggered apoptosis, indicating that ceramide and not ASM per se or sphingomyelin consumption are required for CD95-triggered apoptosis at least in these cells (Cremesti et al., 2001; . ASM deficiency also protected mice from hepatocyte apoptosis, hepatic failure and death upon intravenous injection of agonistic anti-CD95 antibodies or TNFa, indicating the potential in vivo significance of ASM for CD95-and TNF-R-mediated apoptosis.
A molecular model for ASM and ceramide regulation of the cellular stress response Rafts and ceramide It is surprising that ASM and ceramide are functional in so many different biological systems. Although many of these systems are undergoing apoptosis, some involve internalization of bacteria or cellular differentiation. In recent years, we have identified a common mechanism that may explain how ceramide initiates such diverse cellular functions.
The classical fluid mosaic model of Singer and Nicolson (1972) was modified in recent years to accommodate a role for distinct microdomains in the cell membrane, which may serve signaling functions (Simons and Ikonen, 1997). The cell membrane is mainly composed of glycerophospholipids, sphingolipids and cholesterol. The headgroups of sphingolipids trigger a lateral association of lipids of this class with one another, which is further enhanced by hydrophobic interactions between the saturated side chains. Cholesterol seems to fill voids between the large glycerosphingolipids and, critically, tightly interacts with sphingolipids, in particular sphingomyelin, by hydrogen bonding through the C3-hydroxyl group and by hydrophobic interaction of the sterol-ring system with the sphingosine moiety of sphingomyelin. The tight interaction of sphingolipids with one another and with cholesterol results in the segregation of these lipids into discrete membrane structures characterized by a liquid-ordered or even gel-like phase, while glycerophospholipids in the bulk cell membrane reside in a more fluid liquid-disordered phase (for reviews, see Simons and Ikonen, 1997; Brown and London, 1998) .
These distinct sphingolipid-and cholesterol-enriched membrane microdomains are considered to be floating in an 'ocean' of phospholipids, and hence have been termed rafts (Simons and Ikonen, 1997) . Although there is substantial disagreement in the field as to the size of these domains, it is safe to say that they range in size from 30 to 300 nm. Our contribution to this field is the recognition that the consumption of sphingomyelin within rafts to generate ceramide results in a dramatic alteration of these small rafts. Ceramide, which has the unique property of fusing membranes (Brown and London, 1998; Holopainen et al., 1998; Nurminen et al., 2002) , appears to drive the coalescence of raft microdomains to form large, ceramide-enriched membrane platforms, which exclude cholesterol. A mechanism for the formation of ceramide-enriched membrane platforms was indicated from in vitro studies of Holopainen et al. (1998) and Nurminen et al. (2002) . These investigators showed, using a phosphatidylcholine/sphingomyelin-composed unilamellar vesicle system that was locally treated with a sphingomyelinase, that ceramide generation was followed by the formation of patches of ceramide that coalesced rapidly into a ceramide-rich macrodomain. Their studies suggested that this fusagenic function resulted from hydrogen bonding and van der Waal forces between ceramide molecules themselves. The formation of distinct domains in model membranes upon the addition of ceramide was also demonstrated by Huang et al. (1999) , who employed a magnetic resonance spectroscopy technique to demonstrate a transition of fluid phospholipid bilayers into a gel phase upon addition of ceramide. Veiga et al. (1999) similarly revealed that ceramide partitions into distinct domains instead of mixing with phospholipids. Further, ten Grotenhuis et al. (1996) employed atomic force microscopy to show the lateral phase separation of long-chain ceramides in glycerophospholipid/cholesterol bilayers. Finally, our own studies showed the formation of ceramide-enriched membrane platforms in the plasma membrane of live mammalian cells using a monoclonal anticeramideantibody (Grassme´et al., , 2002 Cremesti et al., 2003) . These ceramide-enriched membrane platforms are rapidly formed after CD95 or CD40 stimulation, ionizing radiation (unpublished), UV light, heat, bacterial or viral infections, or after treatment of cells with bacterial sphingomyelinase or natural C 16 -ceramide Cremesti et al., 2003) .
Mechanisms of ceramide generation in rafts Diverse stimuli such as CD95 or CD40, infection with P. aeruginosa, S. aureus or N. gonorrhoeae, g irradiation or heat trigger the rapid appearance of ASM on the extracellular leaflet of the cell membrane coincident with enzyme activation (Esen et al., 2001; Grassme´et al., , 2002 Cremesti et al., 2003; R Kolesnick and E Gulbins, unpublished data) . Although the mechanism(s) of ASM translocation to the cell surface is unknown, we favor the hypothesis that rapid fusion of intracellular vesicles containing ASM with the cell membrane occurs upon contact with the above-mentioned stimuli. The fusion of such vesicles containing ASM results in exposure of ASM on the cell surface. Surface ASM seems to localize to rafts and release ceramide from sphingomyelin, transforming rafts into signaling platforms. This is likely achieved by the ceramide-driven fusion of ceramide-enriched rafts into larger and larger domains, and finally into ceramideenriched platforms, which may in some cells be as large as 10 mm in diameter.
Function of ceramide-enriched membrane platforms Recent results indicate that ceramide-enriched membrane platforms serve to trap and cluster receptor molecules, for example, CD95 (Figure 2, 3) or CD40. In addition, ceramide-enriched platforms seem to play a distinctive role in the cellular response to radiation, UVA light, heat, some chemotherapeutics and infections with pathogenic bacteria (Figure 4 ), viruses and prions, although the exact molecular details, in most instances, are unknown.
The best-studied systems are those involving TNF-R super family members. Clustering of CD95 (Cremesti et al., 2001; ) confers a high local density of the receptor in a small area of the cell membrane permitting oligomerization of the receptor and, critically, its downstream effector molecules, for example, FADD (Chinnaiyan et al., 1995) and caspase 8 (Muzio et al., 1996) . Rapid clustering of CD95 upon stimulation was recently shown in many cell types including lymphocytes, phagocytic cells, granulosa cells of the ovary, epithelial cells, fibroblasts, hepatocytes and thymocytes (Fanzo et al., 2003) (Figures 3, 4) . Some of these cells recruit the receptor to ceramide-enriched membrane domains after stimulation Cremesti et al., 2003) , while other cells, in particular thymocytes (Hueber et al., 2002) , display a constitutive localization of CD95 in rafts. Genetic deficiency of ASM or destruction of ceramide-enriched membrane platforms prevented CD95 clustering and apoptosis, which were restored by the addition of C 16 -ceramide (Cremesti et al., 2001 Grassme´et al., , 2002 . A conceptually similar set of events mediates CD40 signaling with a different biologic outcome. Activation of CD40 results in ASM-mediated ceramide generation, platform formation and the oligomerization of CD40 and activation of its cytoplasmic effectors, for example, JNK or p38-kinase, which drive proliferation. Hence, ceramide-mediated platform formation should be properly viewed as a new mechanism of transmembrane signaling resulting in signal amplification for those stimuli capable of activating ASM in rafts.
Ceramide-enriched membrane rafts may also, in some circumstances, serve to exclude receptor molecules and/ or signaling proteins, facilitating concomitant activation of a specific signaling pathway and the inactivation of antagonistic signaling events. This is consistent with the recent finding that rafts in resting T cells contain approximately 900 proteins, while stimulation of the T-cell receptor/CD3 complex results in concomitant exclusion of approximately 50% of the proteins from rafts (Bini et al., 2003) . It should be emphasized that there is presently no substantive evidence that T-cell receptor cap formation is ASM mediated.
A reorganization of signaling molecules with the exclusion of prosurvival molecules/receptors from, and a recruitment of proapoptotic molecules into ceramideenriched membrane domains, might also mediate apoptotic cell death by radiation, UVA light, heat shock and some chemotherapeutics. Preliminary data from our laboratories show that ionizing radiation and heat induce the formation of ceramide-enriched platforms in the plasma membrane of cells destined to die by apoptosis. Ceramide-enriched membrane platforms may trigger apoptosis after irradiation by recruitment and activation of proapoptotic molecules. However, it is equally plausible that the generation of ceramideenriched membrane platforms upon irradiation or heat results in exclusion from rafts of growth factors and other proteins regulating the survival of the cells. Further, radiation and other forms of stress may trigger ceramide-enriched platforms not only in the cell membrane, but also in intracellular organelles such as the endoplasmic reticulum and mitochondria. Although it is presently unknown whether ceramide-enriched platforms in these organelles play a role in the death response to stress, in preliminary studies, it appears that ceramide generated within the Hela cell mitochondria via activation of ceramide synthase in response to a lethal dose of radiation facilitates Bax insertion through the mitochondrial outer membrane, a prerequisite for cytochrome c release, which commits many cells to apoptosis progression (R Kolesnick et al., unpublished data) .
In summary, we propose that the generation of ceramide-enriched membrane platforms represents an evolutionarily conserved cellular function of ceramide. This does not exclude the additional functions of ceramide, including direct binding to and stiochiometric regulation of proteins. Our hypothesis suggests that extracellular stimuli, for example, proapoptotic receptor molecules or pathogens, employ ceramide-enriched platforms to achieve a critical density of receptors and other signaling molecules that are required for biochemical transfer of the stress across the plasma membrane. We suggest that stimuli that can act within the cell, for example, radiation or heat shock, may also employ similar mechanisms to transmit signals across membranes of intracellular organelles.
Perspectives Many tumors seem to have developed strategies to reduce cellular ceramide concentrations, for example, by glycosylation of ceramide or its deacylation, and this correlates with resistance to chemo-and/or radiotherapy. Thus, strategies to increase the formation of ceramide in tumor cells or endothelial cells of tumor vessels may potentially sensitize tumors to the curative effects of radiation or chemotherapeutics. In this regard, published data from numerous groups now document that strategies that tend to increase cellular ceramide do in fact improve cell killing in numerous different tumors in vitro (Lavie et al., 1996; Michael et al., 1997; Lucci et al., 1998; Spinedi et al., 1998; Liu et al., 2001; Selzner et al., 2001) . Based on these data, Reynolds and Maurer, and Schwartz and co-workers, have received support from the RAID program at the NIH to initiate phase I programs directed at the inhibition of sphingosine kinase to improve the therapeutic outcome in neuroblastoma and colon cancer, respectively (Schwartz et al., 1997; Maurer et al., 2000; Wang et al., 2001) . Similar approaches employing an increased release of ceramide to prevent cellular proliferation or induce cell death might also be useful for the treatment of diseases caused by benign proliferation of cells. In this regard, it has been shown that synthetic ceramides prevent neointimal hyperplasia after a vascular injury and, thus, may help to prevent restenosis (Charles et al., 2000) . In addition, ASM-released ceramide plays a central role in the infection of mammalian cells with at least some pathogenic bacteria and viruses, and the manipulation of ceramide-enriched membrane platforms may alter infection. In particular, internalization or budding of viruses via ceramide-enriched membrane domains might be prevented by inhibition of ASM and cellular ceramide generation. Likewise, some autoimmune syndromes appear blunted in mice lacking ASM and, thus, pharmacologic reduction of cellular ceramide might represent an effective therapeutic approach to treat related autoimmune disorders. A similar approach to ASM inhibition might prove useful in the treatment of acute ischemic disorders, in particular stroke and possibly heart attack, where the tissue at the risk of dying by apoptosis might be preserved by ceramide reduction. Finally, cell death in some acute or chronic degenerative diseases seems to require ceramide, and inhibition of ASM might prove capable of treating these syndromes. It is our belief that the ongoing development of pharmacologic and genetic tools will yield an enhanced mechanistic understanding of the role of sphingolipids in the pathogenesis of disease, and will increase our ability to manipulate these lipids to improve therapeutic outcome. 
